Synergistic anti-tumor effects of the combination of a benzofuroxan derivate and sorafenib on NCI-H460 human large cell lung carcinoma cells

Imagem de Miniatura
Arquivos
art_TEIXEIRA_Synergistic_antitumor_effects_of_the_combination_of_a_2014.PDF (2.26 MB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2014
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
Autores
TEIXEIRA, Sarah Fernandes
AZEVEDO, Ricardo Alexandre de
SALOMON, Maria Alejandra Clavijo
JORGE, Salomao Doria
RODRIGUES, Cecilia Pessoa
PIZZO, Celia Regina
BARBUTO, Jose Alexandre Marzagao
FERREIRA, Adilson Kleber
Citação
BIOMEDICINE & PHARMACOTHERAPY, v.68, n.8, p.1015-1022, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Lung cancer is the most frequent and lethal human cancer in the world. Because is still an unsolved health issue, new compounds or therapeutic strategies are urgently needed. Furoxans are presented as potentials candidates for lung cancer treatment. Accordingly, we evaluated the efficacy of a benzofuroxan derivative, BFD-22, alone and combined with sorafenib against NCI-H460 cell line. We showed that BFD-22 has cytotoxic effects on the NCI-H460 cells. Importantly, the Combination Index (CI) evaluation revels that BFD-22 combined with sorafenib has a stronger cytotoxic effect. In addition, the combination induces apoptosis through extrinsic pathway, leading to TRAIL-R1/DR4-triggered apoptosis. Furthermore, BFD-22 combined with sorafenib increases ROS production and simultaneously reduces perlecan expression in the NCI-H460 cells. In accordance, tumor cells were arrested in the S-phase, and these anti-proliferative effects also inhibit cell migration. This is the first study reporting an advantage of BFD-22 combined with sorafenib as a new therapeutic strategy in the fight against lung cancer.
Palavras-chave
Furoxan, Lung cancer, Apoptosis, BFD-22, Sorafenib, Anti-proliferative
URI
https://observatorio.fm.usp.br/handle/OPI/8894
Referências
  1. Aguirre G, 2005, BIOORGAN MED CHEM, V13, P6336, DOI 10.1016/j.bmc.2005.07.072
  2. Azijli K, 2013, APOPTOSIS, V18, P851, DOI 10.1007/s10495-013-0829-3
  3. Bhojani N, 2008, EUR UROL, V53, P917, DOI 10.1016/j.eururo.2007.11.037
  4. Brose MS, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-349
  5. Cabrera M, 2009, TOXICOL LETT, V190, P140, DOI 10.1016/j.toxlet.2009.07.006
  6. Capdevila J, 2012, ENDOCR-RELAT CANCER, V19, P209, DOI 10.1530/ERC-11-0351
  7. Castro JA, 2006, HUM EXP TOXICOL, V25, P471, DOI 10.1191/0960327106het653oa
  8. Cerecetto H, 2005, MINI-REV MED CHEM, V5, P57
  9. de Wilt LHAM, 2013, CRIT REV ONCOL HEMAT, V85, P363, DOI 10.1016/j.critrevonc.2012.08.001
  10. Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
  11. FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695
  12. GHOSH P, 1981, MED RES REV, V1, P159, DOI 10.1002/med.2610010203
  13. Gollob JA, 2007, J CLIN ONCOL, V25, P3288, DOI 10.1200/JCO.2007.10.8613
  14. Han C, 2013, J MED CHEM, V56, P4738, DOI 10.1021/jm400463q
  15. Holloway GA, 2009, ANTIMICROB AGENTS CH, V53, P2824, DOI 10.1128/AAC.01568-08
  16. Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107
  17. Jorge SD, 2013, EUR J MED CHEM, V64, P200, DOI 10.1016/j.ejmech.2013.03.053
  18. Jorge SD, 2012, MEDCHEMCOMM, V3, P824, DOI 10.1039/c2md20019h
  19. Krauth-Siegel RL, 2003, BIOL CHEM, V384, P539, DOI 10.1515/BC.2003.062
  20. Larkin J, 2013, EXPERT OPIN PHARMACO, V14, P27, DOI 10.1517/14656566.2013.758713
  21. Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
  22. Montanaro G, 2013, BIOORGAN MED CHEM, V21, P2107, DOI 10.1016/j.bmc.2013.01.009
  23. Paz-Ares LG, 2012, J CLIN ONCOL, V30, P3084, DOI 10.1200/JCO.2011.39.7646
  24. Pore MM, 2013, CANCER LETT, V332, P359, DOI 10.1016/j.canlet.2010.09.012
  25. Sartini S, 2012, J MED CHEM, V55, P10523, DOI 10.1021/jm301124s
  26. Schiefer IT, 2012, J MED CHEM, V55, P3076, DOI 10.1021/jm201504s
  27. Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
  28. Society AC, 2014, CANC FACTS FIGURES 2
  29. Stegehuis JH, 2010, DRUG RESIST UPDATE, V13, P2, DOI 10.1016/j.drup.2009.11.001
  30. STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545
  31. Travis WD, 2013, J CLIN ONCOL, V31, P992, DOI 10.1200/JCO.2012.46.9270
  32. Vansteenkiste J, 2013, ANN ONCOL, V24, P89, DOI 10.1093/annonc/mdt241
  33. Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
  34. Zhang JJ, 2012, EXPERT OPIN INV DRUG, V21, P1417, DOI 10.1517/13543784.2012.699039

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/31
Artigos e Materiais de Revistas Científicas - ODS/03